Psychiatry and Neurology, Neurology · Wichita, KS
NPI
1316107964
Since 2008
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
2135 N Collective Ln
Wichita, KS, 67206
Phone (316) 261-3220
Groups this clinician bills Medicare through
Medicare paid, 2024
$174K
15,494 services
Medicare patients, 2024
635
Average age 72
Drug cost, 2024
$1.1M
1,948 prescriptions
Company payments, 2025
$160
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David R Mayans was code J0585 (injection, onabotulinumtoxina, 1 unit), 9,200 times for 17 patients. In total David R Mayans billed 15,494 services in 50 codes, and Medicare paid $174K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-04-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 9,200 | 17 | $4.86 | $45K |
| A9575 Injection, gadoterate meglumine, 0.1 ml | Office | 4,530 | 26 | $0.09 | $414 |
| 99214 Office E&M - Established | Office | 283 | 199 | $80.94 | $23K |
| 95886 Electrical Nerve Conductivity | Office | 267 | 160 | $67.92 | $18K |
| 99205 Office E&M - New | Office | 174 | 174 | $153.43 | $27K |
| 99215 Office E&M - Established | Office | 92 | 78 | $122.11 | $11K |
| 99213 Office E&M - Established | Office | 75 | 71 | $58.89 | $4,417 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 73 | 62 | $12.21 | $891 |
| 99204 Office E&M - New | Office | 59 | 59 | $97.92 | $5,777 |
| 95911 Electrical Nerve Conductivity | Office | 44 | 44 | $145.92 | $6,421 |
| 95910 Electrical Nerve Conductivity | Office | 42 | 42 | $127.38 | $5,350 |
| 95909 Electrical Nerve Conductivity | Office | 36 | 35 | $97.88 | $3,524 |
| 96127 Behavioral Health Services | Office | 31 | 31 | $3.00 | $93.09 |
| 70553 MRI/MRA - Head and Neck | Office | 23 | 23 | $141.20 | $3,248 |
| 95913 Electrical Nerve Conductivity | Office | 16 | 16 | $201.11 | $3,218 |
By year: 2022 $131K for 7,484 services; 2023 $159K for 8,909 services; 2024 $174K for 15,494 services.
Medicare prescription drug claims, 2024
In 2024, the drug David R Mayans prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 217 prescriptions and refills. In total David R Mayans wrote 1,948 Medicare prescriptions that cost $1.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 217 | 341 | 43 | $5,534 |
| Levetiracetam Generic | 178 | 366 | 44 | $5,127 |
| Gabapentin Generic | 150 | 197 | 32 | $2,966 |
| Primidone Generic | 111 | 145 | 22 | $1,315 |
| Topiramate Generic | 97 | 153 | 23 | $702 |
| Aimovig Autoinjector Erenumab-Aooe | 82 | 92 | 12 | $69K |
| Lamotrigine Generic | 60 | 97 | Under 11 | $1,334 |
| Nortriptyline Hcl Generic | 52 | 71 | Under 11 | $926 |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 47 | 65 | Under 11 | $1,104 |
| Amantadine Amantadine Hcl | 42 | 47 | Under 11 | $651 |
| Xembify Immune Globulin,gamma(Igg)klhw | 42 | 42 | Under 11 | $208K |
| Prednisone Generic | 40 | 68 | 11 | $316 |
| Propranolol Hcl Generic | 37 | 71 | Under 11 | $617 |
| Pregabalin Generic | 33 | 53 | Under 11 | $1,126 |
| Emgality Pen Galcanezumab-Gnlm | 33 | 35 | Under 11 | $24K |
Brand drugs: - claims; generic drugs: 1,616 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David R Mayans $160 ($160 in general payments such as food, travel and fees) from 4 companies. The largest payer was Globus Medical, Inc. with $54.69.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.